Custom-Made vaccine takes on liver cancer after surgery

This phase 2 trial tests a personalized dendritic cell vaccine combined with the immunotherapy drug nivolumab in 60 people who had surgery for liver cancer or colorectal cancer that spread to the liver. The vaccine is made from each patient's unique tumor mutations and aims to train the immune system to recognize and destroy any remaining cancer cells. The goal is to see if this combination can improve relapse-free survival and trigger a strong immune response.